In the article by Dünser et al 1 on vasopressin in patients with vasodilatory shock, the authors reported that vasopressin is a pressor agent as efficient as norepinephrine but causing fewer arrhythmias. However, we feel that the conclusion that the combination of norepinephrine and vasopressin proved superior to the infusion of norepinephrine alone is not supported by the data for at least 3 reasons.
Response
The letter by Dr De Backer and colleagues addresses important points of our study. Their speculations about gastric tonometry-derived variables are right and must be considered. However, the fact that macrohemodynamic parameters correlate poorly with microhemodynamic measurements, and that regional gastric mucosal CO 2 partial pressure was also significantly lower in patients receiving arginine vasopressin (AVP), led us to assume that gastric perfusion was better preserved in AVP patients. A recent animal experiment found similar results. 1 After all, Dr De Backer et al are right that gastric tonometry-derived data must be interpreted with extreme caution in these patients with severe shock and multiple organ dysfunction syndrome.
The fear of possible deleterious effects of an AVP-mediated decrease in platelet count is justified and led us to conduct another prospective, still unpublished, study on the effects of a combined infusion of AVP and norepinephrine (NE) on plasmatic and cellular coagulation. Although platelets were again lower in AVP patients, no influence on global coagulation and specific coagulation parameters could be detected.
Regarding the nonsignificant difference in length of intensive care unit stay between study groups, 2 points must be considered. First, after the 48-hour study period, 6 NE patients received AVP, because NE requirements remained Ͼ0.5 g/kg · min Ϫ1 . Second, this study was not planned as an outcome study. To detect a significant decrease in mortality from 66.7% to 56.7%, each study group would have to include 400 patients (Fisher exact test). In accordance with recent animal data, 1 the longer survival time in AVP patients could be an indicator for improved chances of survival in advanced vasodilatory shock treated with a combined AVP/NE infusion.
Our study aimed at examining the effects of a supplemental AVP infusion in advanced vasodilatory shock, defined as a mean arterial pressure Ͻ70 mm Hg despite NE dosages of Ͼ0.5 g/kg · min Ϫ1 . There is no doubt that NE must be considered the first-line vasopressor agent in vasodilatory shock states requiring NE dosages Ͻ0.5 g/kg · min Ϫ1 . However, in our opinion, the results of this study in advanced vasodilatory shock support the conclusion that a combined AVP/NE infusion is superior in stabilizing cardiocirculatory function when the benefit/risk ratio of conventional catecholamine vasopressor agents deteriorates, resulting in a higher incidence of adverse side effects, eg, tachyarrhythmias or myocardial ischemia.
